Palatin Technologies Inc. | |
Stock Exchange | NYSE |
EPS |
$0.02 |
Market Cap |
$222.02 M |
Shares Outstanding |
215.56 M |
Public Float |
191.81 M |
Palatin Technologies Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
198.68 M |
Public Float |
196.67 M |
Address |
Cedar Brook Corporate Center Cranbury New Jersey 08512 United States |
Employees | - |
Website | http://www.palatin.com |
Updated | 07/08/2019 |
Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. It specializes in molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. It offers product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder, which is a type of female sexual dysfunction, defined as low desire with associated distress. |